Brendan Christ Visser, MD
General Surgery · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Visser’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A74028 · Current
Licensed to practise in California · since 2001 · expires 2028-10-31 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$204,179
Medicare paid this office $204,179 for 299 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Other procedure on pancreas | 25 | $42,021 | $1,681 |
| Other procedure on liver using an endoscope | 12 | $25,908 | $2,159 |
| New patient visit (45+ min) | 93 | $11,133 | $120 |
| Removal of gallbladder using an endoscope | 11 | $5,971 | $543 |
| Short return visit (20+ min) | 59 | $5,801 | $88 |
See all 10 services
| Other procedure on pancreas | 25 | $42,021 | $1,681 |
| Other procedure on liver using an endoscope | 12 | $25,908 | $2,159 |
| New patient visit (45+ min) | 93 | $11,133 | $120 |
| Removal of gallbladder using an endoscope | 11 | $5,971 | $543 |
| Short return visit (20+ min) | 59 | $5,801 | $88 |
| Short return visit (20+ min) | 80 | $5,231 | $59 |
| Return visit (30+ min) | 45 | $4,436 | $85 |
| New patient visit (45+ min) | 19 | $2,901 | $153 |
| Return visit (30+ min) | 21 | $2,536 | $121 |
| New patient visit (30+ min) | 14 | $1,025 | $73 |
Procedures Medicare counted
| Upper gastrointestinal (GI) endoscopy for acid reflux | 1-10 | None |
Who their Medicare patients are
299 Original Medicare patients in 2024. Average age 74 · Under 65 7% · 85 and older 7% · Women 45% · Also on Medicaid 21% · Health risk score 1.81. Above the middle of the specialty; the typical general surgery clinician is at 1.69.
Conditions among them: High blood pressure 75% · Diabetes 43% · Coronary heart disease 33% · Chronic kidney disease 30% · Cancer 30% · Atrial fibrillation 25% · Heart failure 19% · Depression 18% · COPD 16% · Stroke 7% · Dementia 6%.
The office billed $1,192,400, Medicare allowed $256,892 and paid $204,179; for 508 services of 47 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 299 | 508 | 74 | 1.81 | $1,192,400 | $204,179 |
| 2023 | 287 | 492 | 74 | 1.89 | $1,067,698 | $194,227 |
| 2022 | 293 | 536 | 74 | 1.58 | $1,038,406 | $187,299 |
| 2021 | 310 | 592 | 73 | 1.89 | $1,019,612 | $184,743 |
| 2020 | 290 | 622 | 73 | 1.88 | $1,302,516 | $230,247 |
| 2019 | 279 | 577 | 72 | 1.85 | $1,257,953 | $233,606 |
| 2018 | 338 | 722 | 73 | 1.88 | $1,452,298 | $264,100 |
| 2017 | 311 | 674 | 72 | 1.91 | $1,399,138 | $261,246 |
| 2016 | 276 | 614 | 72 | 1.93 | $1,118,330 | $213,372 |
| 2015 | 260 | 587 | 72 | 1.92 | $1,089,884 | $199,351 |
| 2014 | 262 | 610 | 72 | 1.82 | $967,950 | $182,518 |
| 2013 | 232 | 499 | 72 | 1.60 | $959,162 | $194,405 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Other procedure on liver using an endoscope | 16 | $29,220 | $1,826 |
| Other procedure on pancreas | 18 | $26,670 | $1,482 |
| Partial removal of pancreas, bile duct, and small bowel with connection of pancreas to small bowel | 11 | $25,732 | $2,339 |
| Short return visit (20+ min) | 151 | $10,959 | $61 |
| New patient visit (45+ min) | 70 | $8,592 | $123 |
| Return visit (30+ min) | 71 | $7,497 | $89 |
| New patient visit (60+ min) | 15 | $2,505 | $167 |
| Long return visit (40+ min) | 11 | $1,463 | $133 |
| New patient visit (30+ min) | 13 | $985 | $76 |
2022: 4 services
| New patient visit (45+ min) | 88 | $10,862 | $123 |
| Short return visit (20+ min) | 139 | $10,734 | $60 |
| Return visit (30+ min) | 59 | $6,738 | $91 |
| New patient visit (30+ min) | 29 | $2,000 | $69 |
2021: 7 services
| Partial removal of pancreas, bile duct, and small bowel with connection of pancreas to small bowel | 11 | $28,353 | $2,578 |
| Other procedure on pancreas | 12 | $16,614 | $1,384 |
| Short return visit (20+ min) | 151 | $12,188 | $59 |
| New patient visit (45+ min) | 91 | $11,642 | $128 |
| Return visit (30+ min) | 77 | $9,700 | $91 |
| New patient visit (60+ min) | 13 | $2,134 | $164 |
| New patient visit (30+ min) | 27 | $2,086 | $77 |
2020: 8 services
| Partial removal of pancreas, bile duct, and small bowel with connection of pancreas to small bowel | 12 | $31,736 | $2,645 |
| New patient visit (45+ min) | 85 | $10,430 | $123 |
| Short return visit (20+ min) | 142 | $8,877 | $48 |
| Return visit (30+ min) | 72 | $7,656 | $74 |
| Repair of abdomen using abdominal lining graft | 15 | $4,223 | $282 |
| Removal of lymph nodes of abdominal organ | 17 | $3,858 | $227 |
| Long return visit (40+ min) | 16 | $1,793 | $105 |
| New patient visit (30+ min) | 25 | $1,751 | $70 |
2019: 6 services
| Partial removal of pancreas, bile duct, and small bowel with connection of pancreas to small bowel | 14 | $33,928 | $2,423 |
| Short return visit (20+ min) | 154 | $9,472 | $46 |
| New patient visit (45+ min) | 62 | $7,230 | $117 |
| Removal of lymph nodes of abdominal organ | 19 | $3,635 | $191 |
| Return visit (30+ min) | 39 | $3,589 | $72 |
| New patient visit (30+ min) | 44 | $2,948 | $67 |
2018: 10 services
| Other procedure on liver using an endoscope | 14 | $26,750 | $1,783 |
| New patient visit (45+ min) | 78 | $8,722 | $112 |
| Short return visit (20+ min) | 133 | $7,869 | $44 |
| New patient visit (30+ min) | 85 | $5,560 | $65 |
| Repair of abdomen using abdominal lining graft | 17 | $5,010 | $295 |
| Removal of lymph nodes of abdominal organ | 16 | $3,357 | $210 |
| Short return visit | 74 | $1,694 | $21 |
| Return visit (30+ min) | 20 | $1,439 | $69 |
| Insertion of feeding tube or tube into upper small bowel | 12 | $1,407 | $117 |
| Ultrasonic guidance during surgery | 19 | $1,047 | $52 |
2017: 12 services
| Partial removal of pancreas, bile duct, and small bowel with connection of pancreas to small bowel | 15 | $40,514 | $2,701 |
| Near total removal of pancreas, bile duct, and small bowel with connection of pancreas to small bowel | 12 | $32,223 | $2,685 |
| Short return visit (20+ min) | 115 | $7,006 | $44 |
| Repair of abdomen using abdominal lining graft | 19 | $5,778 | $304 |
| New patient visit (45+ min) | 49 | $5,660 | $116 |
| New patient visit (30+ min) | 77 | $5,175 | $67 |
| Removal of lymph nodes of abdominal organ | 21 | $4,795 | $228 |
| Short return visit | 75 | $1,908 | $22 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 17 | $1,704 | $90 |
| Other procedure on abdomen | 13 | $1,597 | $123 |
| Ultrasonic guidance during surgery | 26 | $1,403 | $54 |
| Return visit (30+ min) | 12 | $776 | $65 |
2016: 10 services
| Near total removal of pancreas, bile duct, and small bowel with connection of pancreas to small bowel | 13 | $34,199 | $2,631 |
| Partial removal of pancreas, bile duct, and small bowel with connection of pancreas to small bowel | 12 | $31,742 | $2,645 |
| Short return visit (20+ min) | 114 | $6,878 | $43 |
| New patient visit (45+ min) | 59 | $6,556 | $111 |
| New patient visit (30+ min) | 64 | $4,125 | $64 |
| Removal of lymph nodes of abdominal organ | 16 | $3,202 | $200 |
| Ultrasonic guidance during surgery | 34 | $1,798 | $53 |
| Short return visit | 56 | $1,437 | $21 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 14 | $1,312 | $87 |
| Return visit (30+ min) | 12 | $892 | $64 |
2015: 9 services
| New patient visit (45+ min) | 51 | $5,887 | $115 |
| Short return visit (20+ min) | 97 | $5,872 | $46 |
| Repair of abdomen using abdominal lining graft | 15 | $4,565 | $304 |
| New patient visit (30+ min) | 56 | $3,805 | $68 |
| Removal of lymph nodes of abdominal organ | 11 | $2,239 | $204 |
| Short return visit | 68 | $1,824 | $22 |
| Return visit (30+ min) | 22 | $1,751 | $70 |
| Ultrasonic guidance during surgery | 25 | $1,363 | $55 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 14 | $1,256 | $90 |
2014: 8 services
| New patient visit (45+ min) | 51 | $5,734 | $112 |
| Short return visit (20+ min) | 84 | $4,957 | $43 |
| New patient visit (30+ min) | 53 | $3,539 | $67 |
| Repair of abdomen using abdominal lining graft | 11 | $3,338 | $303 |
| Short return visit | 113 | $3,042 | $20 |
| Removal of lymph nodes of abdominal organ | 11 | $2,497 | $227 |
| Return visit (30+ min) | 21 | $1,468 | $70 |
| Ultrasonic guidance during surgery | 16 | $872 | $54 |
2013: 6 services
| Near total removal of pancreas, bile duct, and small bowel with connection of pancreas to small bowel | 11 | $29,276 | $2,661 |
| New patient visit (45+ min) | 35 | $3,837 | $110 |
| New patient visit (30+ min) | 57 | $3,729 | $65 |
| Short return visit (20+ min) | 66 | $3,455 | $42 |
| Short return visit | 95 | $2,672 | $21 |
| Ultrasonic guidance during surgery | 19 | $1,009 | $53 |
Medicaid work
$1,147 in 2023
Medicaid paid $1,147 for 63 billed services this clinician did in 2023, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 63 | $1,147 |
| 2023 | 63 | 1 | 16 | $1,147 |
| 2022 | 24 | 1 | 12 | $460 |
See the largest Medicaid services in earlier years
2022
| Short return visit (20+ min) | 24 | $460 |
Drugs they prescribed that Part D paid
$25,060
Pharmacies billed $25,060 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 118) in 2024. At or below the middle of the specialty; the typical general surgery clinician is at 34%.
80 generic and fewer than 11 brand-name prescriptions · $25,060 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Enoxaparin | 12 | $1,398 | $108 |
Year by year
| 2024 | 118 | 46 | 0% (0) | None | $25,060 |
| 2023 | 102 | 53 | None | None | $31,089 |
| 2022 | 158 | 61 | None | None | $51,027 |
| 2021 | 184 | 63 | 0% (0) | None | $76,135 |
| 2020 | 214 | 59 | None | None | $110,896 |
| 2019 | 195 | 61 | 0% (0) | None | $59,373 |
| 2018 | 281 | 100 | 0% (0) | None | $71,502 |
| 2017 | 261 | 88 | None | None | $73,822 |
| 2016 | 236 | 70 | None | None | $69,088 |
| 2015 | 216 | 66 | None | None | $37,904 |
| 2014 | 231 | 75 | 16% (37) | None | $101,065 |
| 2013 | 330 | 79 | 19% (64) | None | $133,295 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Enoxaparin | 19 | $3,798 | $200 |
2022: 3 drugs
| Creon | 19 | $30,393 | $1,600 |
| Enoxaparin | 33 | $5,561 | $169 |
| Pantoprazole | 23 | $441 | $19 |
2021: 4 drugs
| Creon | 27 | $49,432 | $1,831 |
| Enoxaparin | 31 | $5,650 | $182 |
| Pantoprazole | 17 | $235 | $14 |
| Ondansetron Odt | 11 | $192 | $17 |
2020: 3 drugs
| Creon | 35 | $88,022 | $2,515 |
| Enoxaparin | 21 | $3,816 | $182 |
| Prednisone | 14 | $30 | $2 |
2019: 3 drugs
| Creon | 17 | $21,205 | $1,247 |
| Travasol | 35 | $7,523 | $215 |
| Enoxaparin | 33 | $7,343 | $223 |
2018: 5 drugs
| Creon | 45 | $50,059 | $1,112 |
| Enoxaparin | 38 | $7,333 | $193 |
| Polyethylene Glycol 3350 | 23 | $743 | $32 |
| Pantoprazole | 27 | $233 | $9 |
| Amoxicillin-Clavulanate Potass | 13 | $91 | $7 |
2017: 5 drugs
| Creon | 38 | $47,167 | $1,241 |
| Polyethylene Glycol 3350 | 16 | $533 | $33 |
| Pantoprazole | 24 | $188 | $8 |
| Amoxicillin-Clavulanate Potass | 12 | $162 | $14 |
| Furosemide | 15 | $33 | $2 |
2016: 4 drugs
| Creon | 35 | $34,191 | $977 |
| Enoxaparin | 20 | $8,323 | $416 |
| Polyethylene Glycol 3350 | 19 | $753 | $40 |
| Pantoprazole | 30 | $229 | $8 |
2015: 5 drugs
| Creon | 15 | $12,471 | $831 |
| Enoxaparin | 11 | $9,055 | $823 |
| Spironolactone | 14 | $162 | $12 |
| Pantoprazole | 20 | $149 | $7 |
| Furosemide | 13 | $67 | $5 |
2014: 4 drugs
| Creon | 22 | $23,184 | $1,054 |
| Polyethylene Glycol 3350 | 25 | $957 | $38 |
| Hydrocodone-Acetaminophen | 30 | $413 | $14 |
| Pantoprazole | 30 | $318 | $11 |
2013: 5 drugs
| Enoxaparin | 45 | $50,665 | $1,126 |
| Creon | 48 | $47,343 | $986 |
| Hydrocodone-Acetaminophen | 58 | $611 | $11 |
| Pantoprazole | 27 | $424 | $16 |
| Polyethylene Glycol 3350 | 11 | $311 | $28 |
Money from drug and device companies
$245 in 2025
| 2025 | 3 | 3 | None | $245 |
| 2024 | 2 | 3 | $2,148 | $2,233 |
| 2023 | 2 | 3 | None | $238 |
| 2021 | 1 | 1 | None | $50 |
| 2020 | 1 | 1 | None | $58 |
| 2019 | 2 | 10 | $1,750 | $3,120 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Fujifilm Healthcare Americas | Arietta Precision | $93 | 1 payment
|
| Medtronic | None | $90 | 1 payment
|
| Ethicon | None | $62 | 1 payment
|
See all 3 published payments
| Medtronic | Meals · 2025-11-13 | None | $90 |
| Fujifilm Healthcare Americas | Meals · 2025-02-21 | Arietta Precision | $93 |
| Ethicon | Meals · 2025-01-30 | None | $62 |
See earlier years (2024, 2023, 2021, 2020, 2019)
2024: $2,233
| AstraZeneca Pharmaceuticals LP | None | $2,157 | 2 payments
|
| Ethicon US | Echelon Flex | $76 | 1 payment
|
2023: $238
| Ethicon US | Echelon Flex | $153 | 2 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $85 | 1 payment
|
2021: $50
| Conmed | Abc Handpieces | $50 | 1 payment
|
2020: $58
| Conmed | Abc Handpieces | $58 | 1 payment
|
2019: $3,120
| Sirtex Medical | Sir-Spheres Microspheres | $1,750 | 1 payment
|
| Intuitive Surgical | Da Vinci Surgical System | $1,370 | 9 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novartis Pharmaceuticals Corporation · Pilot Phase 1 Study of Perioperative Peptide Receptor Radionuclide Therapy (Prrt) in Metastatic, Who Grade 1 Or 2, Sstr Positive, Gastroenteropancreatic Neuroendocrine Tumors Who Are Candidates for Cytoreductive Surgery · 2025 | Their institution | $391,272 |
| Novartis Pharmaceuticals Corporation · Pilot Phase 1 Study of Perioperative Peptide Receptor Radionuclide Therapy (Prrt) in Metastatic, Who Grade 1 Or 2, Sstr Positive, Gastroenteropancreatic Neuroendocrine Tumors Who Are Candidates for Cytoreductive Surgery · 2024 | Their institution | $164,400 |
| ABBVIE INC. · Creon (Pancrelipase) Therapy for Subjects With Exocrine Pancreatic Insufficiency (Epi) Due To Pancreatic Cancer: A Double-Blind, Randomized, Parallel Design With 2 Dose Cohorts of Pancrelipase in Resected Pancreatic Cancer Subjects and An Open-Label Single Dose Cohort in Non-Resected Pancreatic Cancer Subjects · 2021 | Their institution | $24,218 |
| ABBVIE INC. · A Study of Creon (Pancrelipase) in Resected and Non-Resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (Epi) · 2022 | Their institution | $3,200 |
| Boston Scientific Corporation · Wf Biliary Preop Drainage Rct · 2019 | Their institution | $2,752 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1134210628
- Licence
- CA A74028California A74028: Current · expires 2028-10-31
- Trained
- University of California, San Francisco School of Medicine, 1999
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Surgery (208600000X)
- Mailing address
- 300 Pasteur Drive, Suite H3680, Standford University School of Medicine, Stanford, CA, 94305
- NPI first listed
- 2006-09-27
- NPI last updated
- 2012-01-30
This is when the NPI record was last certified, not a medical board exam.